HRP20120235T1 - Formulacija tekućeg hormona rasta - Google Patents
Formulacija tekućeg hormona rasta Download PDFInfo
- Publication number
- HRP20120235T1 HRP20120235T1 HR20120235T HRP20120235T HRP20120235T1 HR P20120235 T1 HRP20120235 T1 HR P20120235T1 HR 20120235 T HR20120235 T HR 20120235T HR P20120235 T HRP20120235 T HR P20120235T HR P20120235 T1 HRP20120235 T1 HR P20120235T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation according
- metal salt
- formulation
- growth hormone
- alkaline earth
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract 4
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract 4
- 239000000122 growth hormone Substances 0.000 title claims abstract 4
- 238000009472 formulation Methods 0.000 title claims 27
- 239000000203 mixture Substances 0.000 title claims 27
- 239000007788 liquid Substances 0.000 title 1
- -1 alkali metal salt Chemical class 0.000 claims abstract 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract 6
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract 4
- 239000012669 liquid formulation Substances 0.000 claims abstract 3
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000007979 citrate buffer Substances 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 239000008363 phosphate buffer Substances 0.000 claims abstract 2
- 235000002639 sodium chloride Nutrition 0.000 claims 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 4
- 235000011147 magnesium chloride Nutrition 0.000 claims 4
- 239000007832 Na2SO4 Substances 0.000 claims 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical group OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 3
- 229920001993 poloxamer 188 Polymers 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000001509 sodium citrate Substances 0.000 claims 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 3
- 235000011152 sodium sulphate Nutrition 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 101710142969 Somatoliberin Proteins 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000026500 emaciation Diseases 0.000 claims 1
- 229940025708 injectable product Drugs 0.000 claims 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000012064 sodium phosphate buffer Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Tekuća formulacija naznačena time da sadržihormon rasta, ili otpuštajući hormon hormona rasta (GHRH), koji stimulira otpuštanje ili potencira aktivnost endogenog hGH; sol alkalijskog metalasol zemnoalkalijskog metala ili sol pseudo zemnoalkalijskog metala; tecitratni/fosfatni pufer, pri čemu je pH formulacije u rasponu od 5,5 - 5,8. Patent sadrži još 24 patentna zahtjeva.
Claims (25)
1. Tekuća formulacija naznačena time da sadrži
a) hormon rasta, ili otpuštajući hormon hormona rasta (GHRH), koji stimulira otpuštanje ili potencira aktivnost endogenog hGH;
b) sol alkalijskog metala
c) sol zemnoalkalijskog metala ili sol pseudo zemnoalkalijskog metala; te
d) citratni/fosfatni pufer, pri čemu je pH formulacije u rasponu od 5,5 – 5,8.
2. Formulacija prema zahtjevu 1, naznačena time da hormon rasta je humani hormon rasta.
3. Formulacija prema bilo kojem od zahtjeva 1-2, naznačena time da je sol alkalijskog metala odabrana iz skupine koja sadrži NaCl, KCl, Na2SO4, Na2CO3.
4. Formulacija prema zahtjevu 3, naznačena time da je sol alkalijskog metala NaCl ili Na2SO4.
5. Formulacija prema bilo kojem od zahtjeva 1-4, naznačena time da je sol zemnoalkalijskog metala odabrana iz skupine koja sadrži CaCl2, MgCl2, MgSO4, NH4CO3.
6. Formulacija prema zahtjevu 5, naznačena time da je sol zemnoalkalijskog metala MgCl2.
7. Formulacija prema bilo kojem od zahtjeva 1-6, naznačena time da je pufersko sredstvo natrij citratni/natrij fosfatni pufer.
8. Formulacija prema zahtjevu 7, naznačena time da je pufer u koncentraciji u rasponu od 1 do 100 mM ili od 5 do 50 mM ili od 10 do 20 mM.
9. Formulacija prema bilo kojem od zahtjeva 1-8, naznačena time da nadalje sadrži surfaktant.
10. Formulacija prema zahtjevu 9, naznačena time da surfaktant je polietilen-polipropilen glikol.
11. Formulacija prema zahtjevu 10, naznačena time da surfaktant je Pluronic F68.
12. Formulacija prema zahtjevu 10 ili 11, naznačena time da sadrži polietilen-polipropilen glikol u koncentraciji u rasponu od 0,5 do 5 mg/ml ili 1 do 2 mg/ml ili 1,5 mg/ml.
13. Formulacija prema bilo kojem od zahtjeva 1-12, naznačena time da nadalje sadrži stabilizator.
14. Formulacija prema zahtjevu 13, naznačena time da stabilizator je sukroza.
15. Formulacija prema zahtjevu 14, naznačena time da sadrži sukrozu u koncentraciji u rasponu od 10 mg/ml do 100 mg/ml ili 20 mg/ml do 80 mg/ml ili oko 60 mg/ml.
16. Formulacija prema bilo kojem od zahtjeva 1-15, naznačena time da nadalje sadrži konzervans.
17. Formulacija prema zahtjevu 16, naznačena time da sadrži konzervans u koncentraciji u rasponu od 1 do 10 mg/ml ili 2 do 5 mg/ml ili 3 mg/ml.
18. Formulacija prema zahtjevu 16 ili 17, naznačena time da je konzervans fenol.
19. Formulacija prema bilo kojem od zahtjeva 1 do 18 naznačena time da navedena formulacija ima pH od 5,8 i sadrži r-hGH, natrij citrat/natrij fosfat, Na2SO4, MgCl2, fenol, Pluronic F68, te proizvoljno vodu za ubrizgavanje.
20. Formulacija prema bilo kojem od zahtjeva 1 do 18 naznačena time da navedena formulacija ima pH od 5,8 i sadrži r-hGH, natrij citrat/natrij fosfat, NaCl, MgCl2, fenol, Pluronic F68, te proizvoljno vodu za ubrizgavanje.
21. Farmaceutski pripravak naznačen time da sadrži formulaciju prema bilo kojem od zahtjeva 1 do 20.
22. Prezentacijski oblik tekuće formulacije prema bilo kojem od zahtjeva 1 do 20 naznačen time da je hermetički zatvoren u sterilnim uvjetima unutar spremnika pogodnog za pohranjivanje prije uporabe.
23. Uporaba formulacije prema bilo kojem od zahtjeva 1 do 20 naznačena time da je za dobivanje lijeka za liječenje nedostatka hormona rasta kod djece, gubitak težine i mršavljenje kod pacijenata sa AIDS-om, za Turnerov sindrom kod djevojčica, kao i za kronično zatajenje bubrega kod djece.
24. Uporaba formulacije prema zahtjevu 23 naznačena time da lijek je za primjenu u jednostrukoj dozi.
25. Uporaba formulacije prema zahtjevu 23 naznačena time da lijek je za primjenu u višestrukim dozama.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101444 | 2004-04-07 | ||
| PCT/EP2005/051448 WO2005105148A2 (en) | 2004-04-07 | 2005-03-30 | Liquid growth hormone formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120235T1 true HRP20120235T1 (hr) | 2012-04-30 |
Family
ID=34928942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120235T HRP20120235T1 (hr) | 2004-04-07 | 2012-03-14 | Formulacija tekućeg hormona rasta |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7662393B2 (hr) |
| EP (1) | EP1740213B9 (hr) |
| JP (1) | JP4991522B2 (hr) |
| KR (1) | KR101120879B1 (hr) |
| CN (1) | CN100574801C (hr) |
| AT (1) | ATE547121T1 (hr) |
| AU (1) | AU2005237775B2 (hr) |
| BR (1) | BRPI0508798A (hr) |
| CA (1) | CA2559918A1 (hr) |
| CY (1) | CY1113834T1 (hr) |
| DK (1) | DK1740213T3 (hr) |
| EA (1) | EA010626B1 (hr) |
| ES (1) | ES2383994T3 (hr) |
| HK (1) | HK1098708A1 (hr) |
| HR (1) | HRP20120235T1 (hr) |
| IL (1) | IL178416A (hr) |
| MX (1) | MXPA06011029A (hr) |
| NO (1) | NO337249B1 (hr) |
| PL (1) | PL1740213T3 (hr) |
| PT (1) | PT1740213E (hr) |
| RS (1) | RS52310B (hr) |
| SI (1) | SI1740213T1 (hr) |
| UA (1) | UA89781C2 (hr) |
| WO (1) | WO2005105148A2 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1174457B1 (en) * | 1999-12-03 | 2004-12-22 | Toray Industries, Inc. | Biaxially stretched polyester film for forming |
| RU2009140731A (ru) * | 2007-04-04 | 2011-05-10 | Тератекнолоджиз Инк. (Ca) | Фармацевтические составы, содержащие молекулы ghrh |
| AU2011208620B2 (en) | 2010-01-22 | 2015-04-16 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
| AU2011208625C1 (en) | 2010-01-22 | 2022-08-18 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| EP2736490A1 (en) | 2011-07-25 | 2014-06-04 | Sandoz AG | Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein |
| US8871713B2 (en) * | 2013-03-01 | 2014-10-28 | Theratechnologies Inc. | Formulations of growth hormone releasing factor (GRF) molecules with improved stability |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
| WO2017159540A1 (ja) * | 2016-03-14 | 2017-09-21 | Ｊｃｒファーマ株式会社 | 血清アルブミン－２０ｋ成長ホルモン融合タンパク質 |
| AU2018314767B2 (en) * | 2017-08-08 | 2024-03-21 | Csl Behring Ag | Hemopexin formulations |
| WO2024026224A1 (en) | 2022-07-29 | 2024-02-01 | University Of Rochester | Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3325223A1 (de) | 1983-07-13 | 1985-01-24 | Hoechst Ag, 6230 Frankfurt | Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung |
| JPS60123426A (ja) * | 1983-12-07 | 1985-07-02 | Eisai Co Ltd | 経鼻投与用セクレチン製剤 |
| AU575153B2 (en) * | 1984-04-09 | 1988-07-21 | Du Pont Merck Pharmaceutical Company, The | Pharmaceutical compositions and method for treatment for prophylaxis of cardiac disorders |
| PT83095B (en) * | 1985-07-30 | 1987-12-23 | Int Minerals & Chem Corp | Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers |
| US5681814A (en) * | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| HUT67319A (en) * | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
| SE9201073D0 (sv) | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
| ATE359824T1 (de) * | 1992-07-31 | 2007-05-15 | Genentech Inc | Wässrige formulierung enthaltend menschliches wachstumshormon |
| JPH0892125A (ja) * | 1994-09-21 | 1996-04-09 | Nippon Chem Res Kk | 水性医薬組成物 |
| AUPN801296A0 (en) * | 1996-02-12 | 1996-03-07 | Csl Limited | Stabilised growth hormone formulation and method of preparation thereof |
| US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6759393B1 (en) * | 1999-04-12 | 2004-07-06 | Pfizer Inc. | Growth hormone and growth hormone releasing hormone compositions |
| CZ200260A3 (cs) * | 1999-07-12 | 2002-04-17 | Grandis Biotech Gmbh | Formulace růstového hormonu |
| TWI283182B (en) * | 2000-08-07 | 2007-07-01 | Nektar Therapeutics | Inhalable spray dried 4-helix bundle protein powders having minimized aggregation |
| DE60232987D1 (de) * | 2001-11-14 | 2009-08-27 | Durect Corp | Injizierbare depotzusammensetzungen |
| CN1668332A (zh) * | 2002-07-09 | 2005-09-14 | 桑多斯股份公司 | 包含苯酚的含高浓度人生长激素的液体制剂 |
| WO2004082707A2 (en) * | 2003-03-18 | 2004-09-30 | Ares Trading Sa | Stabilisation of growth hormones in solution |
-
2005
- 2005-03-30 UA UAA200611724A patent/UA89781C2/uk unknown
- 2005-03-30 US US11/578,136 patent/US7662393B2/en active Active
- 2005-03-30 CA CA002559918A patent/CA2559918A1/en not_active Abandoned
- 2005-03-30 ES ES05774044T patent/ES2383994T3/es active Active
- 2005-03-30 EA EA200601874A patent/EA010626B1/ru not_active IP Right Cessation
- 2005-03-30 AU AU2005237775A patent/AU2005237775B2/en active Active
- 2005-03-30 AT AT05774044T patent/ATE547121T1/de active
- 2005-03-30 PL PL05774044T patent/PL1740213T3/pl unknown
- 2005-03-30 MX MXPA06011029A patent/MXPA06011029A/es active IP Right Grant
- 2005-03-30 WO PCT/EP2005/051448 patent/WO2005105148A2/en active Application Filing
- 2005-03-30 DK DK05774044.1T patent/DK1740213T3/da active
- 2005-03-30 PT PT05774044T patent/PT1740213E/pt unknown
- 2005-03-30 JP JP2007506768A patent/JP4991522B2/ja active Active
- 2005-03-30 CN CN200580012183A patent/CN100574801C/zh active Active
- 2005-03-30 RS RS20120218A patent/RS52310B/en unknown
- 2005-03-30 BR BRPI0508798-8A patent/BRPI0508798A/pt active Search and Examination
- 2005-03-30 KR KR1020067018952A patent/KR101120879B1/ko not_active IP Right Cessation
- 2005-03-30 SI SI200531493T patent/SI1740213T1/sl unknown
- 2005-03-30 EP EP05774044A patent/EP1740213B9/en active Active
-
2006
- 2006-10-03 IL IL178416A patent/IL178416A/en active IP Right Grant
- 2006-11-06 NO NO20065097A patent/NO337249B1/no not_active IP Right Cessation
-
2007
- 2007-06-13 HK HK07106383.5A patent/HK1098708A1/xx not_active IP Right Cessation
-
2012
- 2012-03-14 CY CY20121100258T patent/CY1113834T1/el unknown
- 2012-03-14 HR HR20120235T patent/HRP20120235T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120235T1 (hr) | Formulacija tekućeg hormona rasta | |
| US11872266B2 (en) | Rapid-acting insulin compositions | |
| RU2373953C2 (ru) | Стабилизированная композиция, содержащая полипептид фактора vii | |
| ES2402864T3 (es) | Prevención de infección por VIH con TMC278 | |
| ES2221706T3 (es) | Sistema mejorado para la administracion de farmacos a superficies mucosas. | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| ES2414982T7 (es) | Tratamiento a largo plazo de infección por VIH con TCM278 | |
| KR20180033276A (ko) | 신속-작용 인슐린 조성물 | |
| RU2013138672A (ru) | Способ, композиция и набор для чистки кишечника | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| HRP20110801T1 (hr) | Tekući oblik fsh | |
| US6414033B1 (en) | Drug dosage form based on the teorell-meyer gradient | |
| AR047108A1 (es) | Formulacion farmaceutica para tratar afecciones vaginales en humanos, composicion para tratar una infeccion vaginal y metodo para tratar dicha infeccion vaginal | |
| CA2934859A1 (en) | Stable compositions of peptide epoxy ketones | |
| ES2716990T3 (es) | Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago | |
| HRP20120483T1 (hr) | Formulacije peg interferona beta | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| HRP20220896T1 (hr) | Liofilizirana farmaceutska formulacija i njena upotreba | |
| CN101198350A (zh) | 含胃动素样肽的稳定的缓冲的药物组合物 | |
| MXPA04004907A (es) | Composiciones de acetaminofen. | |
| AR022462A1 (es) | Uso de un agente que disminuye el colesterol | |
| JP6704702B2 (ja) | ヨウ素系殺菌成分を含有する水性外用組成物 | |
| ES2791360T3 (es) | Composiciones oftálmicas que comprenden iota-carragenina | |
| PL201844B1 (pl) | Musujący środek farmaceutyczny zawierający metamizol | |
| JP2019532927A5 (hr) |